BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 7, Issue 12
  • This Article
Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review
©The Author(s) 2015.
World J Hepatol. Jun 28, 2015; 7(12): 1632-1651
Published online Jun 28, 2015. doi: 10.4254/wjh.v7.i12.1632
Table 4 Ongoing randomised phase II-III trials aimed at changing the standard of care in hepatocellular carcinoma management during the period 2012-2013[10]
IndicationRandomised studies
AdjuvantSorafenib vs placebo
Intermediate HCCChemoembolisation ± sorafenib
Chemoembolisation ± brivanib
Chemoembolisation ± everolimus
Advanced HCC
First lineSorafenib ± erlotinib
Sorafenib vs brivanib
Sorafenib vs sunitinib
Sorafenib vs linifanib
Sorafenib ± yttrium-90
Sorafenib ± doxorubicin
Second lineBrivanib vs placebo
Everolimus vs placebo
Ramucirmab vs placebo
HCC: Hepatocellular carcinoma.
Full Size Table
Write to the Help Desk
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.